2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapyAssessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice?
Abels E, Adkins B, Cedeno K, Booth G, Allen E, Stephens L, Woo J, Tormey C, Jacobs J. Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice? Transfusion Medicine Reviews 2023, 38: 150810. PMID: 38194730, DOI: 10.1016/j.tmrv.2023.150810.Peer-Reviewed Original ResearchAntigen testingEvidence-based recommendationsFetal risksAlloimmunized pregnanciesPoor outcomeHemolytic diseasePractice guidelinesDecades-old practiceNarrative reviewTransfusion medicineUnnecessary riskRecent evidencePregnancyUnited StatesFetusesRiskCurrent United StatesValuable alternativeTesting algorithmObstetriciansCurrent landscapeDiseaseRecommendations
2022
Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2020
Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn
Gupta GK, Balbuena-Merle R, Hendrickson JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion And Apheresis Science 2020, 59: 102946. PMID: 32962917, DOI: 10.1016/j.transci.2020.102946.Peer-Reviewed Original ResearchConceptsRed blood cellsHemolytic diseaseCurrent pathophysiologic mechanismsSetting of pregnancyPeri-partum periodPregnant patientsRBC alloantibodiesPathophysiologic mechanismsTransfusion practiceAlloantibody detectionTransfusion therapyClinical impactAlloimmunizationTransfusion communityBlood bankPregnancyDeadliest formBlood cellsAlloantibodiesFetusesDiseaseLaboratory toolPatientsTherapySettingPreventing transfusion‐associated graft‐versus‐host disease with blood component irradiation: indispensable guidance for a deadly disorder
Loingsigh S, Flegel WA, Hendrickson JE, Tormey CA. Preventing transfusion‐associated graft‐versus‐host disease with blood component irradiation: indispensable guidance for a deadly disorder. British Journal Of Haematology 2020, 191: 653-657. PMID: 32738068, PMCID: PMC9128360, DOI: 10.1111/bjh.17016.Peer-Reviewed Original Research
2018
Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future
Bahar B, Tormey CA. Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future. Archives Of Pathology & Laboratory Medicine 2018, 142: 662-667. PMID: 29684286, DOI: 10.5858/arpa.2016-0620-rs.Peer-Reviewed Original Research
2017
A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization
Celli R, Schulz W, Hendrickson JE, Tormey CA. A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sanguinis 2017, 112: 469-472. PMID: 28337751, DOI: 10.1111/vox.12515.Peer-Reviewed Original Research
2015
Routine non‐ABO blood group antigen genotyping in sickle cell disease: the new frontier in pretransfusion testing?
Tormey CA, Hendrickson JE. Routine non‐ABO blood group antigen genotyping in sickle cell disease: the new frontier in pretransfusion testing? Transfusion 2015, 55: 1374-1377. PMID: 26094720, DOI: 10.1111/trf.13065.Peer-Reviewed Original Research
2009
Clinical trials for pathogen reduction in transfusion medicine: A review
McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.Peer-Reviewed Original ResearchConceptsClinical trialsBlood productsDonor screening programsDonor blood productsRisk of transmissionInfective donorsTransfusion recipientsScreening programClinical settingInfectious diseasesTransfusion medicineTesting regimensPI treatmentTrialsScreening assaysRiskPathogensPotential toxicityPromising strategyDetection of pathogensRegimensPathogen reductionSensitive methodDiseaseRecipients